ReviewInternational journal of preventive medicine2014
Prevention and Management of Chronic Hepatitis B.
Review in International journal of preventive medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06589167 (Metabolic Dysfunction Among Egyptian Patients with Chronic HBV), which is not on this map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Metabolic Dysfunction Among Egyptian Patients with Chronic HBV
Who cites it
12 citing papers in PubMed, 22 citations in OpenAlex.
- Liver histology pattern of young patients with inactive chronic hepatitis b virus infection from a hospital in South West Nigeria.BMC gastroenterology · 2024Article
- "Titer of anti-HBs in health professions trainees: prevalence of antibody coverage in a University of Central Italy".Human vaccines & immunotherapeutics · 2022Observational
- Possible Paternal Hepatitis B Virus Infection with Different Clinical Courses between Siblings: A Report of Two Cases.Case reports in hepatology · 2022Article
- Article
- Yinchenhao decoction for chronic hepatitis B: Protocol for a systematic review and meta-analysis.Medicine · 2019Article
- Association between Severity of Liver Disease, Frequency ofThe American journal of tropical medicine and hygiene · 2018Article
- A novel absorption spectrometric method, based on graphene nanomaterials, for detection of hepatocellular carcinoma-specific T lymphocyte cells.International journal of nanomedicine · 2018Article
- Advances in the genome-wide association study of chronic hepatitis B susceptibility in Asian population.European journal of medical research · 2017Review
- A cross-sectional survey comparing a free treatment program for advanced schistosomiasis japonica to a general assistance program.Parasitology research · 2017Article
- Vitamin E for the treatment of children with hepatitis B e antigen-positive chronic hepatitis: A systematic review and meta-analysis.World journal of hepatology · 2017Article
- The Effects of Taoren-Honghua Herb Pair on Pathological Microvessel and Angiogenesis-Associated Signaling Pathway in Mice Model of CCl4-Induced Chronic Liver Disease.Evidence-based complementary and alternative medicine : eCAM · 2016Article
- The demographic and paraclinical characteristics of patients with hepatitis B presenting to Shahid Mohammadi Hospital and Clinic and other private clinics in Bandar Abbas, Iran.Journal of advanced pharmaceutical technology & researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic hepatitis B virus (HBV) infection affects an estimated 370 million people worldwide. HBV is endemic throughout the world, and insidiously causes liver damage over years and decades without any warning symptoms or signs. Up to 25-35% of infected individuals eventually die due to complications of liver cirrhosis and hepatocellular carcinoma (HCC) induced by HBV. Screening those individuals at risk of acquiring hepatitis B, and universal vaccination for prevention, would help in limiting the spread and public health repercussions of the virus. Although many new antiviral therapies have been developed for the management of hepatitis B, they still do not offer the possibility of cure. Most individuals who begin oral suppressive therapy will be indefinitely treated. Continuous suppression of HBV replication in individuals with advanced liver disease prolongs life, decreases the need for liver transplantation, and potentially reduces the risk for HCC. In this clinical review, we present a practical approach to prevention of HBV, its natural history and life cycle, as well as its management.
Indexed as
Identifiers
26622990PMC4635410W2248148595What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.